GLP-1 use hits record high as Medicare opens access to weight-loss drugs
Friday, July 10 – The share of U.S. adults taking GLP-1 medications to lose weight has reached a record 11%.
Societies combine to issue recommendations on use of incretin drugs in obesity therapy
Friday, July 10 – Obesity and dietitian societies have joined forces to issue a new consensus statement on recommendations surrounding the use of obesity drugs for weight loss treatment. The statement, which is published in The Lancet Diabetes & Endocrinology, is led by Dr. Laurence Dobbie of the Department of Population Health Sciences, King’s College London, with an international team of 26 authors.
Medicare prescriptions for Wegovy jumped after approval for heart disease
Friday, July 10 – Medicare prescriptions for Wegovy increased sharply after the program started covering the anti-obesity medication to prevent heart problems, but just a fraction of beneficiaries likely eligible received the treatment, according to new research published in the American Journal of Managed Care by the USC Schaeffer Center for Health Policy & Economics.
GLP-1s and Liver Cancer Recurrence; IBS Acupuncture; Transmural Healing in Crohn’s
Friday, July 10 – (MedPage Today) — Diabetes patients with hepatocellular carcinoma (HCC) experienced longer time to HCC recurrence and longer survival when they initiated a GLP-1 agonist rather than a DPP-4 inhibitor, a target trial emulation study found. (Gut…
The Ozempic and Wegovy mistake sending thousands to poison control
Thursday, July 9 – Poison control calls involving semaglutide (Ozempic and Wegovy) soared after the drug was approved for weight management, with researchers linking the increase to accidental dosing mistakes rather than intentional misuse. Simple education about proper weekly dosing and gradual dose increases could help prevent many of these avoidable incidents.
Record High GLP-1 Use; Intense Interval Exercise; Endometriosis and Androgens
Thursday, July 9 – (MedPage Today) — Americans’ use of GLP-1 injectables for weight loss reached a record high, nearly quadrupling since 2024, according to a national Gallup poll.
For patients with type 2 diabetes and peripheral artery disease, GLP-1 receptor agonists…
Medicare GLP-1 Bridge program may lead to bone problems
Thursday, July 9 – The new Medicare GLP-1 Bridge program offers broader, more affordable access to weight loss drugs to address the growing obesity crisis. But there’s a catch when it comes to bone health.
GLP-1 ‘secret shopper’ study finds gaps in online prescribing
Thursday, July 9 – Getting a GLP-1 prescription online can be quick and convenient, but new research suggests it may come with surprisingly little medical oversight. The findings are published in the journal JAMA.
Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending
Thursday, July 9 – New data on Hengrui Pharma and Kailera Therapeutics’ investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission in China, but analysts pointed to high rates of nausea and vomiting that could challenge the ongoing U.S. study.
Survodutide weight-loss drug may reduce harmful fat while preserving muscle
Wednesday, July 8 – Survodutide weight-loss drug may reduce harmful fat while preserving muscle